![]() |
|
|
Vol. 31, Issue 5, 580-588, May 2003
Biopharmaceutical and Pharmacokinetic Research Laboratories,
Fujisawa Pharmaceutical Co., Ltd., Osaka, Japan (Y.N., S.T., A.K.); and
Graduate School of Pharmaceutical Sciences, The University of Tokyo,
Tokyo, Japan (Y.S.)
We investigated hepatic in vitro intrinsic clearance (CLint,in
vitro) in freshly isolated or cryopreserved hepatocytes and compared with CLint,in vivo by using nine model compounds,
FK1052, FK480, diazepam, diltiazem, troglitazone, quinotolast,
FK079, zidovudine, and acetaminophen, in rats and humans. The compounds showed a broad range of in vivo hepatic extraction ratios (rat, 0.05-0.93; humans, 0.03-0.76) and were metabolized by hepatic P450,
UDP-glucuronosyltransferase, sulfotransferase, and/or esterase. CLint,in vitro was determined from substrate
disappearance rate at 1 µM in hepatocytes. CLint,in vivo
was calculated from in vivo pharmacokinetic data using two frequently
used mathematical models (the well stirred and dispersion models). When
estimating rat CLint,in vitro in freshly isolated
hepatocytes, the rat scaling factor values (CLint,in
vivo/CLint,in vitro) showed marked difference among
the model compounds (0.2-73.1-fold). The rat CLint,in
vitro values in freshly isolated hepatocytes were in good
agreement with these in cryopreserved hepatocytes. Human CLint,in
vitro were determined by use of cryopreserved hepatocytes. When
human CLint,in vitro was regarded as the predicted
CLint,in vivo, the observed and predicted CLint,in
vivo for FK1052, FK480, troglitazone, and FK079 differed
markedly (12.4-199.0-fold). In contrast, using human CLint,in
vitro corrected with the rat scaling factors yielded better
predictions of CLint,in vivo that were mostly within 5-fold of the actual values. These results make the evaluation using hepatocytes more useful and provide a basis for predicting hepatic clearance using hepatocytes.